EBPL

Emopamil-binding protein-like · Q9BY08 · EBPL on Sugi Atlas →

384 patent compounds predicted against EBPL, 300 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
[18F]Fluspidine (SCHEMBL29873189)	1.00	1/20
[11C]Sa4503 (SCHEMBL968642)	0.86	1/20
[11C]Sa4503 (SCHEMBL29358558)	0.86	1/20
[11C]Sa4503 (SCHEMBL1299046)	0.84	1/20
Hydrochloric Acid (SCHEMBL8088187)	0.84	1/20
[11C]Sa4503 (SCHEMBL29358694)	0.84	1/20
SCHEMBL8083210	0.81	1/20
SCHEMBL8251796	0.80	1/20
SCHEMBL8086559	0.80	1/20
Hydrochloric Acid (SCHEMBL8075024)	0.79	1/20
Hydrochloric Acid (SCHEMBL1299456)	0.78	1/20
Hydrochloric Acid (SCHEMBL8086545)	0.78	1/20
SCHEMBL8075010	0.76	1/20
SCHEMBL1299348	0.76	1/20
Hydrochloric Acid (SCHEMBL8074974)	0.76	1/20
Hydrochloric Acid (SCHEMBL8075041)	0.76	1/20
Hydrochloric Acid (SCHEMBL1298925)	0.74	1/20
Hydrochloric Acid (SCHEMBL8088180)	0.74	1/20
SCHEMBL17000433	0.74	1/20
SCHEMBL1298738	0.73	1/20

Clinical trials — most relevant to EBPL by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
NEO100 and High-Grade Meningioma	PHASE2	RECRUITING
Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity	PHASE2	RECRUITING
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load	PHASE1	COMPLETED
EKLF Gene Expression in β-thalassemia	nan	NOT_YET_RECRUITING
Impact of Seasonal Malaria Chemoprevention on Immunity Against Malaria Among Children in Northern Benin	nan	COMPLETED
Detection of Krupple Like Factor -1(KLF1/ EKLF) DNA Mutations in Beta Thalassemia Patients	nan	NOT_YET_RECRUITING
Esophageal String Test in Eosinophilic Esophagitis	nan	ACTIVE_NOT_RECRUITING
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Pumilio1 (PUM1) Expression, Sickle Cell Anemia, β-thalassemia Intermedia	nan	NOT_YET_RECRUITING
The Value of circRNAs (hsa_circ_0004001) in Early Diagnosis of HCC	nan	UNKNOWN
Inflamation, Gut Leakage, Iron Status After 6000m Ergometer Test in Elite Rowers.	nan	COMPLETED
Large-scale COVID-19 Population Screening	nan	UNKNOWN
Evaluation of CEMIP in Pancreatic Cancer	nan	UNKNOWN
Fatty Acid Binding Proteins and Markers of Cellular Senescence in Cancer Survivors	nan	NOT_YET_RECRUITING
Mild Intermittent Hypoxia and Its Multipronged Effect on Sleep Apnea	nan	RECRUITING
BATokines as Biomarkers of Brown Fat in Humans	nan	ACTIVE_NOT_RECRUITING
DCLK1 as a Marker/Indicator of Stem Cell Response in Barrett's Esophagus/Esophageal Adenocarcinoma	nan	COMPLETED
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population	nan	COMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
A-protein Levels in Adult and Pediatric Brain Tumor Patients	nan	COMPLETED
Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins.	nan	UNKNOWN
Familial Partial Lipodystrophy Study	nan	COMPLETED
FoxO3a and PU.1 in Acute Lymphoblastic Leukemia	nan	UNKNOWN
Hydroxychloroquin (HCQ) in chILD of Genetic Defect	nan	COMPLETED
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients.	nan	COMPLETED
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors	nan	COMPLETED
Cerebellar Mutism Syndrome Study	nan	RECRUITING
Zinc and the Synthesis of Zinc Binding Proteins (Protocol B)	nan	COMPLETED
Biological Signatures Resulting From Occupational Exposure to Complex Mixtures of PAHs	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a EBPL binder may also engage these)

Protein	Name	Similarity
Q9D0P0	—	0.993	Q9D0P0 →
Q9FTZ2	—	0.970	Q9FTZ2 →
TMEM97	Sigma intracellular receptor 2	0.959	landscape →
Q9JI99	—	0.954	Q9JI99 →
Q4R8A8	—	0.951	Q4R8A8 →
B0BNG2	—	0.951	B0BNG2 →
P58749	—	0.950	P58749 →
A6QL84	—	0.949	A6QL84 →
Q3U3R4	—	0.948	Q3U3R4 →
Q3TD49	—	0.947	Q3TD49 →
Q99P55	—	0.946	Q99P55 →
Q9H8P0	—	0.945	Q9H8P0 →
Q9BZW4	—	0.944	Q9BZW4 →
Q78S06	—	0.944	Q78S06 →
Q8WUD6	—	0.944	Q8WUD6 →
Q1LZE6	—	0.944	Q1LZE6 →
A4K2N5	—	0.943	A4K2N5 →
Q86UW1	—	0.943	Q86UW1 →
Q8N2H4	—	0.943	Q8N2H4 →
Q4R7X9	—	0.943	Q4R7X9 →
D2HBV9	—	0.942	D2HBV9 →
Q9D1E5	—	0.942	Q9D1E5 →
Q8R1J1	—	0.942	Q8R1J1 →
Q66H21	—	0.941	Q66H21 →
SPPL2B	Signal peptide peptidase-like 2B	0.941	landscape →
Q5ND56	—	0.941	Q5ND56 →
Q5PQL3	—	0.941	Q5PQL3 →
Q9QZE9	—	0.941	Q9QZE9 →
Q5RBY7	—	0.941	Q5RBY7 →
Q9JIT0	—	0.941	Q9JIT0 →